These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19207325)

  • 21. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient satisfaction and duration of effect with PLLA: a review of the literature.
    Palm MD; Goldman MP
    J Drugs Dermatol; 2009 Oct; 8(10 Suppl):s15-20. PubMed ID: 19891117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
    Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
    HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
    Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A;
    HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
    Guaraldi G; Orlando G; De Fazio D; De Lorenzi I; Rottino A; De Santis G; Pedone A; Spaggiari A; Baccarani A; Borghi V; Esposito R
    Antivir Ther; 2005; 10(6):753-9. PubMed ID: 16218175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
    Shuck J; Iorio ML; Hung R; Davison SP
    Plast Reconstr Surg; 2013 Mar; 131(3):499-506. PubMed ID: 23142937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly-L-lactic acid: an overview.
    Simamora P; Chern W
    J Drugs Dermatol; 2006 May; 5(5):436-40. PubMed ID: 16703779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy.
    Wildemore JK; Jones DH
    Dermatol Surg; 2006 Nov; 32(11):1407-9; discussion 1409. PubMed ID: 17083596
    [No Abstract]   [Full Text] [Related]  

  • 31. The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
    Wang AS; Babalola O; Jagdeo J
    J Drugs Dermatol; 2014 Mar; 13(3):288-90. PubMed ID: 24595573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly-l-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman.
    Burgess CM
    Dermatol Surg; 2009 May; 35(5):881-4. PubMed ID: 19389088
    [No Abstract]   [Full Text] [Related]  

  • 34. Injectable poly-L-lactic acid for cosmetic enhancement: learning from the European experience.
    Butterwick K; Lowe NJ
    J Am Acad Dermatol; 2009 Aug; 61(2):281-93. PubMed ID: 19615539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
    Duracinsky M; Leclercq P; Herrmann S; Christen MO; Dolivo M; Goujard C; Chassany O
    BMC Infect Dis; 2014 Sep; 14():474. PubMed ID: 25178390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soft tissue augmentation using sculptra.
    Humble G; Mest D
    Facial Plast Surg; 2004 May; 20(2):157-63. PubMed ID: 15643584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-dimensional digital surface imaging measurement of the volumizing effect of injectable poly-L-lactic acid for nasolabial folds.
    Lowe P; Lowe NJ; Patnaik R
    J Cosmet Laser Ther; 2011 Apr; 13(2):87-94. PubMed ID: 21401382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The face of HIV and AIDS: can we erase the stigma?
    Kavouni A; Catalan J; Brown S; Mandalia S; Barton SE
    AIDS Care; 2008 Apr; 20(4):485-7. PubMed ID: 18449827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Canadian study of the use of poly-L-lactic acid dermal implant for the treatment of hill and valley acne scarring.
    Sapra S; Stewart JA; Mraud K; Schupp R
    Dermatol Surg; 2015 May; 41(5):587-94. PubMed ID: 25915626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients.
    Palm MD; Woodhall KE; Butterwick KJ; Goldman MP
    Dermatol Surg; 2010 Feb; 36(2):161-70. PubMed ID: 20039924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.